Thus, our data broaden the potential clinical use of anti-CD38 immunotherapies to treat CD38high lymphoid cancer cells and support the combinations with ATRA to treat CD38low cancers that are sensitive to ATRA. The gene discussed is CD38; the disease is cancer.